Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea

Trial Identifier: D5180R00020
Sponsor: AstraZeneca
Start Date: November 2026
Primary Completion Date: October 2029
Study Completion Date: October 2029

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

No locations posted.